Prescient Therapeutics Limited (PTX.AX)
- Previous Close
0.0580 - Open
0.0580 - Bid 0.0520 x 400000
- Ask 0.0530 x 1960600
- Day's Range
0.0520 - 0.0580 - 52 Week Range
0.0440 - 0.1050 - Volume
1,126,758 - Avg. Volume
1,157,390 - Market Cap (intraday)
41.877M - Beta (5Y Monthly) 1.10
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0100 - Earnings Date Feb 22, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Prescient Therapeutics Limited, a clinical stage oncology company, develops novel drugs for the treatment of various cancers in Australia. Its lead drug candidate is PTX-200, which is in Phase 2a clinical trial for HER2-negative breast cancer, Phase IB/2 clinical trial in relapsed and refractory AML, and Phase 1b in recurrent or persistent platinum-resistant ovarian cancer; and PTX-100, a RhoA inhibitor, for hematological and solid malignancies that focuses on cancers with Ras and RhoA mutations. It has a strategic collaboration with The University of Texas MD Anderson Cancer Center to develop blood cancer binder for OmniCAR. The company was formerly known as Virax Holdings Limited and changed its name to Prescient Therapeutics Limited in December 2014. The company was incorporated in 1986 and is based in Melbourne, Australia.
ptxtherapeutics.comRelated News
Performance Overview: PTX.AX
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: PTX.AX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: PTX.AX
Valuation Measures
Market Cap
41.88M
Enterprise Value
23.44M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
1.85
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-2.03
Financial Highlights
Profitability and Income Statement
Profit Margin
-248.74%
Return on Assets (ttm)
-20.79%
Return on Equity (ttm)
-32.67%
Revenue (ttm)
3.11M
Net Income Avi to Common (ttm)
-7.74M
Diluted EPS (ttm)
-0.0100
Balance Sheet and Cash Flow
Total Cash (mrq)
18.44M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-5.28M
Company Insights: PTX.AX
PTX.AX does not have Company Insights